• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

778.36 +25.24 (+3.35%)
Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 879,091
Open 758.16
Bid (Size) 778.80 (40)
Ask (Size) 783.00 (40)
Prev. Close 753.12
Today's Range 755.21 - 781.84
52wk Range 553.87 - 859.34
Shares Outstanding 91,779,465
Dividend Yield 0.48%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top S&P500 movers in Wednesday's session ↗
October 14, 2026
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
October 12, 2026
Via Chartmill

Performance

52-Week Range 9.4% below 52-week high
778.36
553.8752W Low 859.3452W High
1 Week 0.4% below 1-week high
723.651W Low 781.841W High

Regeneron Pharmaceuticals (REGN) traded between $553.87 and $859.34 over the past 52 weeks and last traded at $778.36, 9.4% below its 52-week high. Over the past week it ranged between $723.65 and $781.84.

Past 12 Months
+5.2%
-1.9%
+17.1%
+3.2%
+0.3%
+35.9%
1W +$38.79
1M -$15.38
3M +$113.91
6M +$24.43
YTD +$2.05
1Y +$205.76

REGN was +35.9% over the past year, +3.2% over six months, +0.3% year to date, +5.2% in the last week.

12 Months vs Market
REGN
+35.9%
DIA
+11.4%
SPY
+16.2%
QQQ
+21.9%
IWM
+9.5%

Over the past 12 months REGN returned +35.9% versus DIA (Dow) +11.4%, SPY (S&P 500) +16.2%, QQQ (Nasdaq 100) +21.9% and IWM (Russell 2000) +9.5%.

Volume & Liquidity 1.19× 3-mo avg
Today 879,091 3-mo avg 740.9K
1W
618.6K
1M
759.8K
3M
740.9K
6M
866.8K
YTD
823.1K
1Y
861.6K

REGN most recently traded 879,091 shares against a 3-month average daily volume of 740.9K.

More News

Read More
News headline image
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
October 12, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
October 06, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Stock Is Trading Lower Today
October 01, 2026
Via StockStory
Which S&P500 stocks are moving on Thursday? ↗
October 01, 2026
Via Chartmill
News headline image
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
October 01, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
October 01, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
October 01, 2026
Via MarketBeat
Topics ETFs
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
October 01, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
September 30, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗
September 28, 2026
Via The Motley Fool
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
September 28, 2026
Via StockStory
News headline image
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
September 24, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
September 23, 2026
Via MarketBeat
Topics ETFs
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
September 22, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
September 22, 2026
Via StockStory
Topics Stocks
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 15, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
September 14, 2026
Via MarketBeat
Topics Intellectual Property
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 14, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
September 14, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗
September 12, 2026
Via MarketBeat
Topics ETFs
News headline image
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
September 11, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
September 10, 2026
From Robbins Geller Rudman & Dowd LLP
Via Business Wire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 778.36
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 10/14/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 71.44B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 71B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap